Cargando…
Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients
Cefazolin is an antibiotic frequently used for perioperative prophylaxis. Data from healthy adults and pediatric surgery patients were pooled to refine a previously developed population pharmacokinetic (PK) model and to determine the optimal body weight cutoff for selecting fixed doses of either 1 o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049034/ https://www.ncbi.nlm.nih.gov/pubmed/33202066 http://dx.doi.org/10.1002/jcph.1785 |
_version_ | 1783679351438442496 |
---|---|
author | Schmitz, Michael L. Rubino, Christopher M. Onufrak, Nikolas J. Martinez, Diana Valencia Licursi, Diane Karpf, Angela Cetnarowski, Wes |
author_facet | Schmitz, Michael L. Rubino, Christopher M. Onufrak, Nikolas J. Martinez, Diana Valencia Licursi, Diane Karpf, Angela Cetnarowski, Wes |
author_sort | Schmitz, Michael L. |
collection | PubMed |
description | Cefazolin is an antibiotic frequently used for perioperative prophylaxis. Data from healthy adults and pediatric surgery patients were pooled to refine a previously developed population pharmacokinetic (PK) model and to determine the optimal body weight cutoff for selecting fixed doses of either 1 or 2 g cefazolin to produce exposures in pediatric surgery patients similar to a single 2‐g dose in adults. Regardless of dose used, cefazolin was well tolerated in pediatric patients. A total of 1102 plasma samples from 62 patients from 3 studies were available to assess the previous model. The pooled data set allowed for simplification of the model such that allometrically scaled clearance and volume parameters were found to provide a robust fit while removing unnecessary covariate relationships. Monte Carlo simulations using the final cefazolin population PK model suggested an optimal weight cutoff of 50 kg, in contrast to the previously suggested 60 kg for a single 2‐g dose. Patients at or above this 50‐kg cutoff would receive a 2‐g dose of cefazolin, and those below 50 kg but ≥25 kg would receive a 1‐g dose of cefazolin. |
format | Online Article Text |
id | pubmed-8049034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80490342021-04-20 Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients Schmitz, Michael L. Rubino, Christopher M. Onufrak, Nikolas J. Martinez, Diana Valencia Licursi, Diane Karpf, Angela Cetnarowski, Wes J Clin Pharmacol Pediatric Pharmacology Cefazolin is an antibiotic frequently used for perioperative prophylaxis. Data from healthy adults and pediatric surgery patients were pooled to refine a previously developed population pharmacokinetic (PK) model and to determine the optimal body weight cutoff for selecting fixed doses of either 1 or 2 g cefazolin to produce exposures in pediatric surgery patients similar to a single 2‐g dose in adults. Regardless of dose used, cefazolin was well tolerated in pediatric patients. A total of 1102 plasma samples from 62 patients from 3 studies were available to assess the previous model. The pooled data set allowed for simplification of the model such that allometrically scaled clearance and volume parameters were found to provide a robust fit while removing unnecessary covariate relationships. Monte Carlo simulations using the final cefazolin population PK model suggested an optimal weight cutoff of 50 kg, in contrast to the previously suggested 60 kg for a single 2‐g dose. Patients at or above this 50‐kg cutoff would receive a 2‐g dose of cefazolin, and those below 50 kg but ≥25 kg would receive a 1‐g dose of cefazolin. John Wiley and Sons Inc. 2020-12-09 2021-05 /pmc/articles/PMC8049034/ /pubmed/33202066 http://dx.doi.org/10.1002/jcph.1785 Text en © 2020 B. Braun Medical Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Pediatric Pharmacology Schmitz, Michael L. Rubino, Christopher M. Onufrak, Nikolas J. Martinez, Diana Valencia Licursi, Diane Karpf, Angela Cetnarowski, Wes Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients |
title | Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients |
title_full | Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients |
title_fullStr | Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients |
title_full_unstemmed | Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients |
title_short | Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients |
title_sort | pharmacokinetics and optimal dose selection of cefazolin for surgical prophylaxis of pediatric patients |
topic | Pediatric Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049034/ https://www.ncbi.nlm.nih.gov/pubmed/33202066 http://dx.doi.org/10.1002/jcph.1785 |
work_keys_str_mv | AT schmitzmichaell pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients AT rubinochristopherm pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients AT onufraknikolasj pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients AT martinezdianavalencia pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients AT licursidiane pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients AT karpfangela pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients AT cetnarowskiwes pharmacokineticsandoptimaldoseselectionofcefazolinforsurgicalprophylaxisofpediatricpatients |